Compare NetEase Inc (NTES) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs ResMed Inc. — how do they compare? NetEase Inc trades at $116.51 (market cap $74.79B), while ResMed Inc. trades at $219.5 (market cap $31.73B). The key difference: NetEase Inc is far larger — about 2.4× ResMed Inc.'s market cap, and NetEase Inc pays the higher dividend (2.53%). Which is the better fit depends on your goals.
| NTES | RMD | |
|---|---|---|
Market Cap | $74.79B | $31.73B |
Sector | Media | Health |
52-Week High | $159.34 | $283.28 |
52-Week Low | $109.26 | $182.82 |
Enterprise Value | $50.53B | $31.08B |
Dividend Yield | 2.53% | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTES trades at $119.45, up 0.13% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 EPS of $1.77, missing expectations of $2.32, though revenue grew 8% year-over-year to $4.4 billion. Strong fundamentals include a 27.88% net income margin and $137.58 billion in cash, supporting dividend growth and AI investments.
Outlook is mixed: analyst consensus is strongly bullish (82% buy ratings), citing undervaluation and international expansion potential, but near-term risks include earnings volatility and competitive pressures in gaming. The stock offers value at a P/E of 15.93, yet technical weakness suggests cautious entry points near support at $117.
ResMed (RMD) trades at $221.05, down 3.2% on the day, with a bearish technical signal and key support at $218. The company reported strong Q4 2026 results, beating EPS estimates at $2.95, and maintains robust profitability with a 26.94% net income margin. Revenue growth remains solid, reaching $5.15B in 2025, though weak 2027 sales guidance has pressured the stock. A dividend of $0.66 is scheduled for payment in September 2026.
Outlook is mixed: strong fundamentals and a consensus price target of $235.70 suggest upside, but bearish technicals and investor lawsuits pose near-term risks. The stock offers value with a P/E of 21.19, yet competitive and regulatory challenges require monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
